NAD+ (injectable)
naturally occurring coenzyme (a dinucleotide, not a peptide)
Also called: copper peptide, copper tripeptide-1, glycyl-L-histidyl-L-lysine copper, Iamin (former wound-gel brand)
GHK is a three-amino-acid peptide found in human plasma, saliva and urine that binds copper tightly; GHK-Cu is the copper complex. It is a common ingredient in skin-care products and has been studied for wound healing and skin remodeling.
It is popular in the looks-and-longevity corner of gym culture for skin, hair and 'collagen', and it shows up in recovery blends alongside BPC-157 and TB-500.
Human evidence: limited. There are small topical skin studies with mixed results; there are no published controlled trials of injected GHK-Cu.
Not named on the 2026 Prohibited List. Some analysts note injectable use could fall into a gray zone under catch-all language, but no specific listing exists.
Uncertain. Topical skin-care use is generally regarded as low risk. Injectable 'research' GHK-Cu is not explicitly banned, but tested lifters should check with Global DRO or USADA before relying on that. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not FDA-approved as a drug (it is a common cosmetic ingredient). FDA had GHK-Cu for injectable routes in Category 2 of the interim 503A list; it was removed from Category 2 in the April 15, 2026 action. FDA's May 14, 2026 categories list shows 'GHK-Cu (except for injectable routes of administration)' reinstated to Category 1 on May 5, 2026, so non-injectable compounding falls under the interim policy. FDA plans to consult the advisory committee on GHK-Cu before the end of February 2027.
As of 2026-10-01.
Not named on the 2026 Prohibited List. Some analysts note injectable use could fall into a gray zone under catch-all language, but no specific listing exists. Uncertain. Topical skin-care use is generally regarded as low risk. Injectable 'research' GHK-Cu is not explicitly banned, but tested lifters should check with Global DRO or USADA before relying on that. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.
Not FDA-approved as a drug (it is a common cosmetic ingredient). FDA had GHK-Cu for injectable routes in Category 2 of the interim 503A list; it was removed from Category 2 in the April 15, 2026 action. FDA's May 14, 2026 categories list shows 'GHK-Cu (except for injectable routes of administration)' reinstated to Category 1 on May 5, 2026, so non-injectable compounding falls under the interim policy. FDA plans to consult the advisory committee on GHK-Cu before the end of February 2027.
Limited. There are small topical skin studies with mixed results; there are no published controlled trials of injected GHK-Cu.
Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.
naturally occurring coenzyme (a dinucleotide, not a peptide)
synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice
synthetic peptide based on thymosin beta-4, an actin-binding protein found in most cells